News

Timing of Cytoreductive Surgery Impacts Outcomes in Advanced Ovarian Cancer

ASCO 2025: A Noninvasive Diagnostic Tool for Ovarian Cancer

AACR 2025: Are OTTA-SPOT Scores an Accurate Prognostic Tool for Black Patients With Ovarian Cancer?

Significant Overall Survival Benefit Seen With Mirvetuximab Soravtansine vs Chemotherapy in FRα-Positive, Platinum-Resistant Ovarian Cancer

Clinical Impact of Variation in HRR Gene Mutations in High-Grade Serous Tubo-Ovarian Carcinoma

Repeated Laparoscopic Extensive Surgery for Rare Ovarian Cancer: Case Report

Translational Data From Early-Phase Trial of Novel Immunotherapy for Advanced Ovarian Cancer

FDA Grants Fast Track Designation to Novel Therapy for Platinum-Resistant Ovarian Cancer

Reproductive Factors and Risk of Epithelial Ovarian Cancer in Asian Women

Australian Clinical Trial to Assess Next-Generation Screening Test for Ovarian Cancer

Variations in Worldwide Patterns and Trends in Ovarian Cancer

Can Metabolic Imaging Discern Subtypes in High-Grade Serous Ovarian Cancer?

Molecular and Immune Disparities in High-Grade Serous Ovarian Cancer

RMAT Designation Granted by the FDA for Gemogenovatucel-T in Advanced Ovarian Cancer

FOLR1 as a Therapeutic Target in Low-Grade Serous Ovarian Carcinoma

Phase II PICCOLO Trial: Mirvetuximab Soravtansine-gynx in FRα-Positive, Platinum-Sensitive Ovarian Cancer

Use of Niraparib in Ovarian Cancer: Benefits of an Individualized Starting Dose

Genomic Instability: Linked to Survival Outcomes in BRCA1/2 Wild-Type Ovarian Cancer

Research Focuses on How to Boost Immunotherapy Response in Recurrent Ovarian Cancer

Real-World Analysis of FRα Testing Patterns in Epithelial Ovarian Cancer

Can Genomic Instability Predict Response to PARP Inhibitors in Ovarian Cancer?

Team at Wyss Institute Receives Award for New Treatment Paradigm in Ovarian Cancer

Can Targeting SMARCA4 Overcome Ovarian Cancer Immune Evasion?

SOLO3 Survival Update: Olaparib vs Nonplatinum Chemotherapy for Relapsed Ovarian Cancer

Epithelial Ovarian Cancer: Comparing Targeted Treatments With Standard-of-Care Chemotherapy

Understanding the Phenotypic Characteristics of Normal and Malignant Ovarian Cells

LANCE Trial to Compare Surgical Methods After Chemotherapy for Epithelial Ovarian Cancer

High-Grade Serous Ovarian Cancer: Molecular and Immune Diversity of mRNA Subtypes

Update on Overall Survival in Phase III Trial of Niraparib for Advanced Ovarian Cancer